Jiongjie He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jiongjie He has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Feng Yang
Lanzhou Institute of Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences
1 shared publicationFenyi He
Gansu Institute of Animal Nutrition
1 shared publicationHuilin Guo
Gansu Provincial Center for Animal Disease Prevention and Control
1 shared publication- Jiongjie He
Key Laboratory of New Animal Drug Project, Gansu Province, Key Laboratory of Veterinary Pharmaceutical Development, Ministry of Agriculture and Rural Affairs, Lanzhou Institute of Husbandry and Pharmaceutical Sciences of Chinese Academy of Agriculture Sciences, Lanzhou 730050, China
1 shared publication - Ling Wang
Key Laboratory of New Animal Drug Project of Gansu Province, Key Laboratory of Veterinary Pharmaceutical Development, Ministry of Agriculture and Rural Affairs, Lanzhou Institute of Husbandry and Pharmaceutical Sciences of Chinese Academy of Agriculture Sciences, Lanzhou 730050, China
1 shared publication - Shengyi Wang
Key Laboratory of New Animal Drug Project of Gansu Province, Key Laboratory of Veterinary Pharmaceutical Development, Ministry of Agriculture and Rural Affairs, Lanzhou Institute of Husbandry and Pharmaceutical Sciences of Chinese Academy of Agriculture Sciences, Lanzhou 730050, China
1 shared publication
Latest Publications
- Open Access
Temporal Modulation of Type I Interferon and NF-κB Signaling by Baicalin Suppresses Infectious Bronchitis Virus Replication and Inflammatory Response
Background: Infectious bronchitis virus (IBV) poses a significant threat to poultry health, and exploring effective antiviral agents is of considerable importance. This study aimed to investigate the antiviral activity of baicalin against IBV and its underlying immunomodulatory mechanisms. Methods: The antiviral effect of baicalin was evaluated in chicken embryo kidney cells using various treatment schedules. Viral replication was assessed through nucleocapsid protein expression and viral titers. Mechanistic studies involved analysis of key signaling pathways, IRF3 knockdown experiments, and proteasomal degradation assays. Results: Baicalin (20 µg/mL) significantly inhibited IBV replication, with optimal efficacy observed when administered at 2 h post-infection. The compound demonstrated time-dependent regulation of antiviral and inflammatory pathways, enhancing the MDA5-MAVS-STAT1 axis and IFN-β signaling at late infection stage while showing biphasic modulation of NF-κB pathway. IRF3 was identified as essential for both anti-inflammatory and antiviral effects. Baicalin enhanced IκBα stability by inhibiting its proteasomal degradation. Conclusions: Baicalin suppresses IBV replication through coordinated enhancement of type I interferon response and temporal regulation of NF-κB pathway, with IRF3 serving as a key regulatory molecule. These findings provide mechanistic support for baicalin’s potential as an anti-IBV therapeutic agent.
Open AccessTemporal Modulation of Type I Interferon and NF-κB Signaling by Baicalin Suppresses Infectious Bronchitis Virus Replication and Inflammatory Response
Background: Infectious bronchitis virus (IBV) poses a significant threat to poultry health, and exploring effective antiviral agents is of considerable importance. This study aimed to investigate the antiviral activity of baicalin against IBV and its underlying immunomodulatory mechanisms. Methods: The antiviral effect of baicalin was evaluated in chicken embryo kidney cells using various treatment schedules. Viral replication was assessed through nucleocapsid protein expression and viral titers. Mechanistic studies involved analysis of key signaling pathways, IRF3 knockdown experiments, and proteasomal degradation assays. Results: Baicalin (20 µg/mL) significantly inhibited IBV replication, with optimal efficacy observed when administered at 2 h post-infection. The compound demonstrated time-dependent regulation of antiviral and inflammatory pathways, enhancing the MDA5-MAVS-STAT1 axis and IFN-β signaling at late infection stage while showing biphasic modulation of NF-κB pathway. IRF3 was identified as essential for both anti-inflammatory and antiviral effects. Baicalin enhanced IκBα stability by inhibiting its proteasomal degradation. Conclusions: Baicalin suppresses IBV replication through coordinated enhancement of type I interferon response and temporal regulation of NF-κB pathway, with IRF3 serving as a key regulatory molecule. These findings provide mechanistic support for baicalin’s potential as an anti-IBV therapeutic agent.
- Open Access
- 14 February 2023
- Published by Springer Nature in Research Square
The mechanism of Esculetin inhibiting Infectious Bronchitis Virus replication by Regulating Infectious Bronchitis Virus-induced expression of β-interferon and related cytokines
Infectious bronchitis virus could negatively regulate interferon pathway.Esculetinas the active ingredient inFraxini Cortexhas the effect of inhibiting infectious bronchitis, but its therapeutic mechanism is unknown. Therefore, this study aimed to investigate molecular mechanism of the inhibition of IBV replication byEsculetin. MTT assay was used to determine the cytotoxicity and the inhibitory effect ofEsculetinon IBV proliferation. Real time PCR was used to detect the changes of IBV genomic vector in trachea, lung, intestine, liver, kidney and muscle tissues of the embryo body before and after usingEsculetin .Real time PCR and Western blotting were used to detect the copy number of IBV genome and the effect of IBV on the expression level of related cytokines in the β-interferon signaling pathway before and after treatment withEsculetin. The results suggest thatEsculetinhad a significant inhibitory effect on IBV replication. 10mg/ml Esculetin had the weakest inhibitory effect on cell proliferation and the weakest toxicity. IBV could be detected in all tissues and organs of the embryo body, and the highest virus content was found in lung and trachea tissues .Esculetincan promote the expression of important cytokines in IBV-induced host cell β-interferon signaling pathway and reduce the inhibitory of the expression of MDA5, IFN-β and Mx in the early stage of IBV infection effect, regulate the antagonism of IBV against host cell β-interferon signaling pathway. This study shows thatEsculetincan promote the natural immunity of host cells to achieve antiviral effect. It provided a theoretical basis for theEsculetinto be used as a therapeutic drug for IBV.
- 14 February 2023
- Published by Springer Nature in Research Square
Open AccessThe mechanism of Esculetin inhibiting Infectious Bronchitis Virus replication by Regulating Infectious Bronchitis Virus-induced expression of β-interferon and related cytokines
Infectious bronchitis virus could negatively regulate interferon pathway.Esculetinas the active ingredient inFraxini Cortexhas the effect of inhibiting infectious bronchitis, but its therapeutic mechanism is unknown. Therefore, this study aimed to investigate molecular mechanism of the inhibition of IBV replication byEsculetin. MTT assay was used to determine the cytotoxicity and the inhibitory effect ofEsculetinon IBV proliferation. Real time PCR was used to detect the changes of IBV genomic vector in trachea, lung, intestine, liver, kidney and muscle tissues of the embryo body before and after usingEsculetin .Real time PCR and Western blotting were used to detect the copy number of IBV genome and the effect of IBV on the expression level of related cytokines in the β-interferon signaling pathway before and after treatment withEsculetin. The results suggest thatEsculetinhad a significant inhibitory effect on IBV replication. 10mg/ml Esculetin had the weakest inhibitory effect on cell proliferation and the weakest toxicity. IBV could be detected in all tissues and organs of the embryo body, and the highest virus content was found in lung and trachea tissues .Esculetincan promote the expression of important cytokines in IBV-induced host cell β-interferon signaling pathway and reduce the inhibitory of the expression of MDA5, IFN-β and Mx in the early stage of IBV infection effect, regulate the antagonism of IBV against host cell β-interferon signaling pathway. This study shows thatEsculetincan promote the natural immunity of host cells to achieve antiviral effect. It provided a theoretical basis for theEsculetinto be used as a therapeutic drug for IBV.